Dental Anesthesia: Over 4 Million Doses Injected into the Market, Promises of Anti-Cancer Drug Production by Year-End
BY: Hana Saada
Algiers, September 24, 2023 – In a recent announcement, Mr. Réda Belkacemi, the President of the National Observatory for Monitoring Pharmaceutical Products, addressed the nation on Sunday, shedding light on Algeria’s pharmaceutical future. With a focus on dental anesthesia and groundbreaking developments in anti-cancer drug production, the Algerian healthcare sector is poised for significant transformation.
In a bid to ensure a stable supply of dental anesthesia products, Mr. Belkacemi revealed that the Ministry of Industry and Pharmaceutical Production had taken decisive actions to counter recent market disruptions. These disruptions had been causing concern among healthcare professionals and patients alike in recent weeks.
“A quantity exceeding 4 million doses has been introduced into the market to rectify the situation before the end of September,” stated Mr. Belkacemi. This initiative reflects the government’s commitment to addressing immediate healthcare needs, ensuring that Algerians have access to vital medical resources.
While discussing the broader landscape of pharmaceuticals in Algeria, Mr. Belkacemi made an equally significant announcement about the imminent production of anti-cancer drugs within the country. He disclosed that Algeria is currently nurturing six projects dedicated to the local production of these life-saving medications. These new facilities are set to become operational by the end of the year, marking a pivotal moment for the nation’s healthcare infrastructure.
“We are actively working on these projects, and they are scheduled to commence operations before the close of the current year,” Mr. Belkacemi affirmed. He added that this ambitious endeavor is poised to tackle disruptions and shortages in the anti-cancer drug market, a longstanding concern for patients in Algeria.
Furthermore, Mr. Belkacemi’ statement included a commitment to eliminating market disruptions entirely by 2024. A pivotal component of the pharmaceutical sector’s transformation in Algeria is the ongoing digitalization of the industry. This technological revolution promises to bring greater efficiency and transparency to the market while ensuring rigorous quality control. Mr. Belkacemi emphasized that this digitalization will enable better organization and oversight of pharmaceutical industries throughout Algeria, ultimately benefiting patients and the healthcare system at large.
In conclusion, Algeria is embarking on a groundbreaking journey towards self-reliance in pharmaceuticals, with ambitious plans to produce anti-cancer drugs and stabilize the dental anesthesia market. The commitment to eliminating disruptions and enhancing digitalization reflects a strong dedication to improving healthcare access and quality for all Algerians. As these initiatives progress, the nation can look forward to a brighter and healthier future.
